Main content

    Solid Tumor Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials


    Title: An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

    Description: This is an open-label, multicenter, Phase I/II study to assess the safety, tolerability, and pharmacokinetics of GDC-0032
    Investigator: John Chung-Kai Chan, MD
    Eligibility: Subjects, 18 y/o and older, with histologically documented, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen and are not candidates for regimens known to provide clinical benefit
    Status: Active and open to enrollment
    Contact: Leslie Corona, 415-600-5766, Email: CoronaLA@cpmcri.org about Study Genentech PMT4979g

    Title: A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer
    Description: Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, who have a histologically or cytologically confirmed diagnosis of advanced solid tumor that has relapsed or is refractory to standard curative or palliative therapy or has a contraindication to standard therapy; or who have histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC and have received 1 or 2 lines of prior chemotherapy or targeted therapy for Stage IIIB or IV NSCLC (second- or third-line)
    Status: Active and open to enrollment
    Contact: Leslie Corona, 415-600-5766, Email: CoronaLA@cpmcri.org about Study NanoCarrier

    Title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
    Description: The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks.
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with measurable disease with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
    Status: Active and open to enrollment
    Contact: Leslie Corona, 415-600-5766, Email: CoronaLA@cpmcri.org about Study Serono EMR 200647-001

    Title: Molecular Analysis for Therapy Choice (MATCH)
    Description: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival
    Status: Contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study EAY131

    • updated June 2017

    Back to top